HBM Holdings Ltd. (HK:2142)
:2142
Top Page
HBM Holdings Ltd.
(2142)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$11.00
▼(-8.94% Downside)
Action:ReiteratedDate:10/28/25
The overall stock score of 51 reflects the company's mixed financial performance, characterized by strong gross margins but declining profitability and cash flow issues. Technical analysis indicates a bearish trend with weak momentum, while valuation suggests moderate pricing. The absence of earnings call and corporate events data limits further insights.
Positive Factors
High Gross Margin
An 88.2% gross margin indicates durable product-level pricing power or low direct costs. Over months this margin cushion helps absorb operating expenses, supports funding R&D or commercialization, and provides a structural buffer if revenues falter until topline recovery.
Negative Factors
No Operating Cash Flow
Lack of operating cash generation and zero FCF are structural red flags: recurring operational deficits force reliance on financing or asset sales. Over months this can limit reinvestment, increase dilution or leverage, and constrain the company's ability to fund sustained development or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
An 88.2% gross margin indicates durable product-level pricing power or low direct costs. Over months this margin cushion helps absorb operating expenses, supports funding R&D or commercialization, and provides a structural buffer if revenues falter until topline recovery.
Read all positive factors
HBM Holdings Ltd. (2142) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$12.80B
Dividend YieldN/A
Average Volume (3M)8.63M
Price to Earnings (P/E)5.9
Beta (1Y)1.21
Revenue Growth59.70%
EPS Growth239.97%
CountryHK
Employees183
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.19
Shares Outstanding895,528,500
10 Day Avg. Volume6,681,047
30 Day Avg. Volume8,634,233
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)1.48
Price to Sales (P/S)4.83
P/FCF Ratio6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.00Price Target Upside49.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$220.64M
HBM Holdings Ltd. Business Overview & Revenue Model
Company Description
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal ...
How the Company Makes Money
HBM Holdings Ltd. generates revenue through multiple streams, primarily from rental income derived from its property investments, which include office spaces and commercial real estate. Additionally, the company earns revenue through its financial...
HBM Holdings Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.06M | 38.10M | 89.50M | 40.66M | 4.31M | 14.11M |
| Gross Profit | 59.33M | 33.61M | 87.47M | 40.53M | 4.17M | 13.66M |
| EBITDA | 32.64M | -2.08M | 31.18M | -130.21M | -130.84M | -290.91M |
| Net Income | 37.21M | 2.78M | 22.80M | -137.27M | -137.88M | -296.54M |
Balance Sheet | ||||||
| Total Assets | 380.47M | 215.01M | 228.48M | 232.12M | 282.36M | 388.74M |
| Cash, Cash Equivalents and Short-Term Investments | 320.69M | 167.22M | 140.72M | 171.71M | 216.30M | 356.95M |
| Total Debt | 64.67M | 61.34M | 66.01M | 90.93M | 19.47M | 1.73M |
| Total Liabilities | 96.89M | 90.96M | 108.85M | 139.62M | 59.45M | 27.73M |
| Stockholders Equity | 282.70M | 124.45M | 119.99M | 92.83M | 223.19M | 361.19M |
Cash Flow | ||||||
| Free Cash Flow | -5.75M | 30.44M | -21.60M | -118.40M | -139.81M | -35.99M |
| Operating Cash Flow | -5.70M | 30.68M | -19.12M | -99.96M | -125.61M | -35.39M |
| Investing Cash Flow | 1.75M | 6.55M | 28.09M | 137.59M | -76.90M | -93.53M |
| Financing Cash Flow | -4.32M | -10.24M | -29.14M | 70.58M | 1.59M | 357.86M |
HBM Holdings Ltd. Technical Analysis
Positive
12.08
Price Trends
12.02
Positive
12.71
Positive
12.31
Positive
Market Momentum
0.40
Negative
69.71
Neutral
92.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2142, the sentiment is Positive. The current price of 12.08 is below the 20-day moving average (MA) of 12.34, above the 50-day MA of 12.02, and below the 200-day MA of 12.31, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 69.71 is Neutral, neither overbought nor oversold. The STOCH value of 92.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2142.
HBM Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.02B | 135.64 | 7.17% | ― | 23.37% | ― | |
53 Neutral | HK$8.81B | -76.25 | -6.26% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.80B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:2142
HBM Holdings Ltd.
14.47
9.04
166.48%
HK:9966
Alphamab Oncology
9.04
3.11
52.45%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2256
Abbisko Cayman Limited
13.26
7.07
114.22%
HK:2616
CStone Pharmaceuticals
9.35
7.15
325.00%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.98
-1.10
-13.61%
HBM Holdings Ltd. Corporate Events
HBM Holdings Forecasts Sharp Profit Surge on Recurring Biotech Collaboration Revenue
Feb 4, 2026
HBM Holdings Limited has issued a positive profit alert, indicating that its unaudited profit for the year ended 31 December 2025 is expected to surge to between US$88 million and US$95 million, compared with US$2.7 million a year earlier, with to...
HBM Holdings Launches Up to HK$300 Million On‑Market Share Buyback
Jan 29, 2026
HBM Holdings Limited has announced a plan to repurchase its own shares on the open market, authorising buybacks of up to HK$300 million under its existing and future shareholder-approved repurchase mandates. The board believes the current share pr...
HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise
Jan 19, 2026
HBM Holdings Limited has exercised a warrant obtained under its license and collaboration agreement between its incubated biotech unit HBM Alpha Therapeutics and U.S.-based Spruce Biosciences Inc., converting it into an equity stake in the partner...
HBM Holdings Grants 309,000 Share Options to Non-Connected Employee
Jan 1, 2026
HBM Holdings Limited has granted 309,000 share options to a non-connected employee under its existing share option scheme, with an exercise price of HK$12.76 per share and a 10-year exercise period. The options will vest in three tranches between ...
HBM Holdings Partners with Bristol Myers Squibb for Antibody Development
Dec 17, 2025
HBM Holdings Ltd. has entered into a global strategic collaboration and license agreement with Bristol Myers Squibb to develop next-generation multi-specific antibodies. This partnership could bring Harbour BioMed up to $1.125 billion in payments ...
HBM Holdings Enhances Collaboration with AstraZeneca for Biotherapeutic Development
Nov 24, 2025
HBM Holdings Ltd. has announced an advancement in its global collaboration with AstraZeneca, aimed at discovering and developing next-generation biotherapeutics. The amendment to their existing agreement enhances the scope of their partnership, ma...
HBM Holdings Partners with Pfizer for Antibody Discovery
Nov 19, 2025
HBM Holdings Ltd. has announced a non-exclusive license agreement with Pfizer, allowing Pfizer global access to Nona Biosciences’ HCAb platform for preclinical antibody discovery. This collaboration aims to accelerate the development of full...
HBM Holdings Partners with Umoja Biopharma for CAR-T Cell Development
Nov 5, 2025
HBM Holdings Ltd. has announced a new evaluation and license agreement with Umoja Biopharma to develop in vivo CAR-T cell products. This collaboration combines HBM’s proprietary platforms with Umoja’s VivoVec™ technology, potenti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.